FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	OMB APPR	OVAL							
	OMB Number:	3235-0287							
	Estimated average burden								
1	hours por rosponso:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*						2. Issuer Name and Ticker or Trading Symbol ACELRX PHARMACEUTICALS INC [5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Angotti Vincent J.						ACRX]									X Dire		ctor	10% C		wner	
(Last) (First) (Middle)															X	Office belov	er (give title v)		Other (specify below)		
C/O ACELRX PHARMACEUTICALS, INC. 351 GALVESTON DRIVE						3. Date of Earliest Transaction (Month/Day/Year) 02/28/2019									Chief Executive Officer						
(Street) REDWOOD CITY CA 94063					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)										Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting					
(City)	(St	ate) (2	Zip)													Pers	on				
		Tabl	e I - Non	-Deriv	ative	Se	curiti	es Ac	quired	l, Dis	posed o	of, or	r Ben	efici	ally	Owne	ed				
1. Title of Security (Instr. 3) 2. Transposite (Month/L					//Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)		Code	Transaction Disposed Code (Instr. 5)		ities Acquired (A) d Of (D) (Instr. 3, 4			4 and Secu Bend Own		cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount		(A) or (D)	Price	•	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock 02/28						3/2019					3,234	4	A \$2		.81 257,884(1		7,884 ⁽¹⁾	D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)				Expirat	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)			vative urity	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownershi Form: Direct (D) or Indirect (I) (Instr. 4	t (D) lirect	Beneficial Ownership (Instr. 4)	
				,	Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	or Nur of	ount nber res							

Explanation of Responses:

1. Balance includes non-reportable acquisition of 3,234 shares of Common Stock through the Company's Employee Stock Purchase Plan.

Remarks:

/s/ Martha Adler, Attorney-In-03/04/2019

fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.